HYBRID EVENT: You can participate in person at Rome, Italy or Virtually from your home or work.
September 16-18, 2024 | Rome, Italy
GPMB 2019

Jerry Feitelson

Jerry Feitelson, Speaker at Plant Biology Conferences
Co-Founder/CEO of Agribody Technologies, Inc, United States
Title : A Universal genetic switch for increasing pant yields, stress tolerance and product shelf life


Agribody Technologies, Inc. (ATI) uses genome editing with a highly validated pair of gene targets conserved across plant species to significantly improve seed and biomass yield and increase resistance to abiotic (drought, low nutrients, crowding) and biotic (pathogen) stress, while delaying post-harvest senescence. The efficacy of this technology was consistently proven in multiple crops in lab, greenhouse and field conditions. Two years of replicated field trial data in alfalfa have shown unprecedented 20-45% yield increase in an elite commercial variety with no loss of quality. Similarly, field trials in banana and greenhouse studies in tomato, lettuce and ornamentals have increased shelf-life by 2- to 3-fold. Currently, several licensing and co-development projects with innovative seed companies are currently underway in multiple crops. Results from these various studies will be discussed.


Jerry Feitelson, Ph.D. is Co-Founder/CEO of Agribody Technologies, Inc., an agricultural biotechnology company partnering with innovative seed companies.  He was previously CSO of Global Clean Energy Holdings & Sustainable Oils; Manager of Business Development, IP & Alliances at Beckman Coulter; VP of Technology and Business Development at GenWay Biotech; and Research Director at Akkadix.  At Mycogen, his group discovered and patented most of the B.t. toxin genes.  He was a Senior Research Microbiologist at American Cyanamid and Adjunct Professor at Rutgers University.  Jerry is an inventor on 16 U.S. patents & author of 40 publications. His educational background includes a B.S in Life Sciences at MIT, a Ph.D. in Genetics with Joshua Lederberg at Stanford University School of Medicine, and an NIH postdoctoral research fellowship at the John Innes Institute, Norwich, UK in Streptomyces molecular genetics, where he cloned the first gene involved in antibiotic biosynthesis with a known biochemical role.